Factors which the IRB should take into consideration when evaluating the adequacy of plans include the following: model of plan chosen (independent committee, monitor, the principle investigator) ...

A California-based biotech company is stealing the show on Wednesday after the company announced the data monitoring committee has recommended the continuation of its Phase 3 Sunrize study.